- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SRPT
Recent news which mentions SRPT
From Benzinga
From Motley Fool
Tickers
SRPT
From Motley Fool
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
February 29, 2024
Tickers
SRPT
From Motley Fool
Earnings Scheduled For February 28, 2024
February 28, 2024
From Benzinga
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 19, 2024
From Benzinga
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
February 16, 2024
From Benzinga
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 16, 2024
From Benzinga
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
February 16, 2024
From Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 16, 2024
From Benzinga
2 Magnificent Growth Stocks to Buy With $500
February 15, 2024
From Motley Fool
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
From Benzinga
From Motley Fool
From InvestorPlace
Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts
January 30, 2024
Tickers
SRPT
From Benzinga
Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
January 29, 2024
From Benzinga
Got $3,000? 3 Growth Stocks to Double Up On Right Now
January 26, 2024
From Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
January 25, 2024
From Motley Fool
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
January 22, 2024
From Motley Fool
From InvestorPlace
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
January 10, 2024
Tickers
SRPT
From Benzinga
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
January 09, 2024
From Benzinga
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
January 09, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.